
The thymosin alpha-1 sequence is Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN: 28 amino acid residues with an acetylated N-terminal serine. It corresponds to residues 2–29 of human prothymosin alpha, immediately after the precursor’s initiator methionine.[1] Its C terminus is a free carboxylic acid, not an amide. The molecular formula for this terminally defined peptide is C129H215N33O55; PubChem lists a molecular weight of 3108.3 and a monoisotopic mass of 3106.5041281.[2]
The letters describe the amino acid order; “Ac” describes an end-group modification rather than an additional residue. Keeping those two pieces together distinguishes the natural acetylated peptide from a chain with the same residue order but a free N-terminal amino group.
Where the 28 Residues Sit in Prothymosin Alpha
Human prothymosin alpha is a 111-residue protein. Its curated sequence begins M-S-D-A-A-V-D-T-S-S-E-I-T-T-K. UniProt annotates removal of the initiator methionine in an alternate processed form, N-acetylserine at precursor position 2, and thymosin alpha-1 as the peptide occupying precursor positions 2–29.[1]
This creates two numbering systems. In the isolated 28-mer, the acetylated serine is residue 1; in the precursor, that same serine is residue 2. Peptide Lys14 therefore corresponds to precursor Lys15, and the terminal Asn28 corresponds to precursor Asn29. These positions are read directly from the annotated sequence. The offset matters when comparing a peptide sequence with modification annotations on the parent protein.
The precursor’s listed molecular weight, 12,203 Da, belongs to the 111-residue protein, not to thymosin alpha-1.[1] A precursor entry can identify the peptide’s location without making every property of the full protein a property of the shorter chain.
Historically, thymosin alpha-1 was the first peptide from thymosin Fraction 5 to be completely sequenced and synthesised.[3] It was described and characterised from calf thymus in 1977.[4] That discovery history and the human precursor annotation answer different questions: how the peptide was originally identified, and where its sequence occurs in the human protein.
Composition: Nine Acidic Side Chains, Four Lysines, No Cysteine
Numbering from the acetylated serine gives the following composition, counted directly from the curated sequence.[1]
| Residue | Count | Positions in the 28-mer |
|---|---|---|
| Glutamate, Glu, E | 6 | 10, 18, 21, 24, 25, 27 |
| Aspartate, Asp, D | 3 | 2, 6, 15 |
| Lysine, Lys, K | 4 | 14, 17, 19, 20 |
| Serine, Ser, S | 3 | 1, 8, 9 |
| Threonine, Thr, T | 3 | 7, 12, 13 |
| Alanine, Ala, A | 3 | 3, 4, 26 |
| Valine, Val, V | 3 | 5, 22, 23 |
| Isoleucine, Ile, I | 1 | 11 |
| Leucine, Leu, L | 1 | 16 |
| Asparagine, Asn, N | 1 | 28 |
The sequence carries nine acidic side chains—three Asp and six Glu—against four lysines and one free C-terminal carboxylate. Its N-terminal alpha-amino group is blocked by acetylation. This composition supports the qualitative description of an acidic peptide at neutral pH, consistent with its description as an acidic thymic peptide in the production literature.[5] A peptide’s isoelectric point is the pH at which the summed charges on its ionizable groups balance, and it is computed by applying the Henderson–Hasselbalch equation to a chosen set of residue pKa values; the numerical result therefore depends on which published pKa set and terminal-group assumptions a calculator implements.[6] The sources read here do not reproduce a pKa table or a measured pI for this peptide, so no single value is asserted. Any value obtained from a calculator implementing a published model should be reported together with that model.
There is no cysteine in the sequence, so the chain has no cysteine pair from which to form a disulfide bond. This does not establish that every possible covalent association or chemical alteration is absent. There is also no tryptophan, tyrosine or phenylalanine. What that absence means for detection has to be established for the method at hand; the supplied sources do not establish a detection method for this peptide.
How the Charge Is Distributed Along the Chain

The opening segment, SDAAVDTSSEITT, contains peptide positions 1–13. Asp2, Asp6 and Glu10 supply its acidic residues, while Ser1, Ser8, Ser9, Thr7, Thr12 and Thr13 account for its serine and threonine content. There is no lysine in this segment. The acetyl cap belongs to the first serine and does not change this residue numbering.
The middle segment, KDLKEKK at positions 14–20, contains all four lysines. Asp15 and Glu18 interrupt that basic-residue concentration, but Lys19 and Lys20 are adjacent. A description of the peptide as having no basic cluster fits its N-terminal segment, where residues 1–13 contain no lysine, but that description does not extend to the whole chain: the four lysines are concentrated in the central KDLKEKK segment at positions 14–20.
The final segment, EVVEEAEN at positions 21–28, contains four glutamates, two valines, one alanine and the terminal asparagine. The letter N denotes asparagine’s side chain; it does not mean that the peptide’s C terminus is amidated. The terminal chemical form is a separate structural feature.
These segments explain how an acidic overall composition can coexist with a lysine-rich middle. The negative character is distributed across the chain rather than confined to a single terminal block. This positional reading is derived from the sequence; it does not identify a binding site or demonstrate a particular fold.[1]
N-Terminal Acetylation: Identity, Charge and End-Group Analysis

The natural form of thymosin alpha-1 is N-alpha-acetylated.[5] The acetyl group adds mass and blocks the positive N-terminal amino group. Consequently, the residue string alone is an incomplete description of molecular identity: the acetylated and free-N-terminal chains have the same amino acid order but different end-group chemistry.
That modification has a specific consequence for Edman degradation. This sequencing chemistry requires an available N-terminal amino group; N-terminal acetylation blocks the reaction. The obstacle is therefore the modified terminus, not simply the peptide’s length.[7]
Acetylation is also a production problem. A reviewed recombinant route used a thioredoxin fusion expressed in E. coli, followed by proteolytic cleavage, chemical acetylation and reversed-phase HPLC purification. Another reported fusion with ribosomal protein L12 was only partly N-alpha-acetylated. RimJ was identified as the responsible acetyltransferase, and co-expression with RimJ was proposed as a route toward fully acetylated material.[4]
A separate study applied RimJ-mediated acetylation in vitro to a thymosin alpha-1–human serum albumin fusion expressed in Pichia pastoris. That work concerns a fusion protein, not the isolated 28-mer. It also distinguishes acetylation of the N-terminal amino group from acetylation of lysine side-chain amino groups.[5] These production examples explain why obtaining the residue sequence and obtaining the intended terminal modification are separate tasks. They do not establish an improvement in stability for a particular preparation.
The Numbers Behind the Mass
PubChem’s molecular formula and mass fields describe the N-terminally acetylated, C-terminally unamidated peptide. Its listed molecular weight is 3108.3, while its monoisotopic mass is 3106.5041281. These are distinct computed fields for the same defined molecular structure, not competing experimental measurements.[2]
A comparison with an analytical report therefore needs to identify which mass convention the report uses and which molecular form it describes. The precursor’s mass, the acetylated peptide’s mass and the mass of a differently terminated chain are not interchangeable. Nor does a database formula constitute a measurement of a physical sample’s identity, purity or peptide content.
For LC-MS and MS/MS interpretation, the supported starting information is the residue order, the terminal groups and the computed molecular composition. The supplied evidence contains no peptide-specific LC-MS spectrum, observed charge-state assignment, MS/MS fragment assignment or validated acetylation-localisation procedure. Those missing measurements cannot be replaced by a claimed diagnostic fragmentation pattern.
Trypsin Cleavage: A Prediction from the Sequence
Trypsin cleaves mainly on the carboxyl side of lysine and arginine; a following proline generally inhibits cleavage.[8] Thymosin alpha-1 has lysines at positions 14, 17, 19 and 20, with no arginine or proline. Applying that cleavage rule to the sequence predicts a first fragment spanning residues 1–14: Ac-SDAAVDTSSEITTK.
This is an unmeasured, rule-based prediction, not a reported digest or an observed MS/MS fragment. The acetyl notation is carried over from the starting structure; predicting this fragment does not confirm or localise acetylation. The adjacent lysines also show why cleavage-site positions must be read individually rather than treating the lysine-rich segment as one site.
What the HPLC Evidence Actually Supports
Reversed-phase HPLC was used to purify thymosin alpha-1 obtained through a particular recombinant production route followed by cleavage and chemical acetylation.[4] This supports its reported use as a purification step, but does not provide a retention time or a measured comparison between acetylated and unacetylated forms.
The supplied text provides no peptide-specific column, gradient or retention dataset from which to predict elution order. Likewise, ion-exchange purification reported for the albumin fusion cannot establish the behaviour of the free 28-mer.[5] These are concrete limits on the chromatographic account, not evidence for a particular retention or detection method.
End Groups, Counterions and Net Peptide Content
A free C-terminal carboxylic acid and a C-terminal amide are different covalent terminal structures. The PubChem structure specifies the former for thymosin alpha-1.[2] Changing that terminal group changes the defined molecule; it is not merely a different name for the same salt form.
Counterions and other associated material are a separate issue from the peptide’s covalent sequence. If associated material contributes to a weighed preparation, the total weighed mass is not exclusively peptide mass. The molecular formula of the defined peptide alone therefore cannot supply a preparation’s net peptide content. The supplied sources do not establish counterion identity, water content or net peptide content for any particular preparation; those require batch-specific measurement.
What the Sequence Does Not Establish
UniProt annotates the full prothymosin alpha precursor as disordered. That annotation does not provide an experimentally determined three-dimensional structure for the isolated 28-mer, nor does it establish the fragment’s conformation under every solution condition.[1] The sequence and its charge distribution should not be converted into a claim of a fixed folded structure.
The precursor record also lists phosphorylation sites within the region corresponding to thymosin alpha-1. These are precursor annotations, not evidence that an isolated peptide preparation carries those modifications.[1] Similarly, the immunological literature reviewed for thymosin alpha-1 does not make a sequence string proof of a receptor mechanism or therapeutic effect.[4] Biochemical or production findings on fusion constructs remain findings on those constructs; they do not establish effects in humans.
Related research: What Is Thymosin Alpha-1; Peptide Identity: Sequences, Fragments, Modifications, Salt Forms; Thymosin Alpha-1.
Research Use Only. This article is for laboratory research and analytical education, not a validated experimental protocol or medical or veterinary advice. The described materials are not for administration to humans or animals.
References
- UniProtKB P06454: Human prothymosin alpha
- PubChem CID 16130571: Thymosin alpha-1
- Thymosin alpha1
- Thymosin alpha 1: Biological activities, applications and genetic engineering production
- Production of N-alpha-acetyl Ta1-HSA through in vitro acetylation by RimJ
- Isoelectric point
- Edman degradation
- Trypsin